Bristol-Myers Squibb Company (BMY) Institutional Ownership & Insider Trading

2,509 institutions reported holding Bristol-Myers Squibb Company shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 4 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BMYBristol-Myers Squibb CompanyFollow BMY — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 125.6B
P/E TTM: 13.5
Dividend yield: 4.1%
52-week: —
Next earnings: 29 Oct, in 5 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

2,509 institutions held 81.9% of the shares. Across filers that reported both quarters, shares held changed +1.1%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	2,509	1673	+1.1%	802	107	829	122
Mar 26	2,492	1608	+1.2%	863	184	702	107
Dec 25	2,385	1629	-4.4%	748	198	828	105
Sep 25	2,210	1664	+3.0%	680	99	848	105
Jun 25	2,240	1636	+0.7%	653	96	866	262
Mar 25	2,407	1589	+2.2%	728	122	807	125
Dec 24	2,393	1589	-2.0%	732	143	769	83
Sep 24	2,195	1506	-1.4%	660	207	792	97

Bristol-Myers Squibb Company — questions

Who owns Bristol-Myers Squibb Company stock?: 2,509 institutions reported Bristol-Myers Squibb Company shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (8.8%), VANGUARD CAPITAL MANAGEMENT LLC (6.5%), STATE STREET CORP (5.0%).
Are Bristol-Myers Squibb Company insiders buying or selling?: 4 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Bristol-Myers Squibb Company's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.